AGU654 (Compound 44) is a selective mPGES-1 inhibitor with an IC50 of 2.9 nM against mPGES-1. AGU654 inhibits mPGES-1 to block the pathway converting arachidonic acid into prostaglandin E2 (PGE2) by COX-1/2, thereby alleviating inflammatory responses, pain, and fever. In activated human monocyte-derived macrophages and human whole blood models, AGU654 selectively suppresses bacterial exotoxin-induced PGE2 production while preserving the production of other prostaglandins. In guinea pig models, AGU654 significantly alleviates fever, inflammation, and inflammatory pain, exhibiting excellent anti-inflammatory, analgesic, and antipyretic effects. AGU654 holds promise as a strategy for studying inflammatory diseases and pain.

ADP-β-S (trisodium) is an ADP analog and partial agonist. ADP-β-S (trisodium) induces human platelet aggregation and inhibits PGE1-stimulated adenylate cyclase.

TFC-007, a selective hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, show high inhibitory activity against H-PGDS enzyme (IC50 value of 83 nM). TFC-007 can be used for composing H-PGDS degradation inducer PROTAC(H-PGDS)-1 (TFC-007 binds to H-PGDS, and Pomalidomide binds to cereblon).

UT-11 is a potent microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor, inhibits PGE2 production from human SK-N-AS and murine BV2 cells induced by LPS with IC50 of 0.1 and 2.0 uM, respectively.

TAS-205 (Pizuglanstat, TAS205) is a potent, specific hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with IC50 of 55.8 nM, does not inhibit LPGDS at 100 uM.

TAS-204 (TAS204) is a potent, specific hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, inhibits recombinant human H-PGDS with IC50 of 24.0 nM.

SZ0232 is a small molecule mPGES-2 (microsomal prostaglandin E synthase-2) inhibitor with IC50 of <1 uM, exhibits beneficial effects on modulating β-cell function and glucose metabolism both in vitro and in vivo.

MPO-0144 (MPO 0144) is a potent, selective mPGES-1 inhibitor (PGE2 IC50=41.77 nM, mPGES-1 IC50=1.16 nM), exhibits potent neuroprotection (ED50=3.0 nM) against 6-OHDA-induced in PC12 cells without significant neurotoxicity (IC50>10 uM).

LY3023703 is a potent, highly selective microsomal prostaglandin E synthase 1 (mPGES1) inhibitor, dose-dependently inhibits PGE2 production in human whole blood ex vivo.

MF63 is a selective mPGES-1 inhibitor with an IC50 of 0.9 nM and 1.3 nM for pig mPGES-1 and human mPGES-1 enzyme, respectively.

HPGDS inhibitor 1 is a novel and selective Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50 Value of 0.7 nM.

Vipoglanstat (BI 1029539, GS-248), a carboxamide, is a potent and selective, non-peptide and orally active small molecular inhibitor of human prostaglandin E synthase 1 (mPGES-1). Vipoglanstat (BI 1029539, GS-248) also has anti-inflammatory activity.

Isofezolac (LM 22070) is a non-steroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin-synthetase. Isofezolac anti-inflammatory, and antipyretic properties.

FLP 62064 is a potent 5-lipoxygenase (5-LOX) and COX-2 dual inhibitor. FLP 62064 has potently anti-inflammatory activity.

Brp-201 is considered as a promising therapeutic target for the next generation of anti-inflammatory drugs in the treatment of inflammatory diseases. It is a new, effective and selective inhibitor of mPGES-1 with an IC50 value of 0.42 μM.

Clopirac is a potent and orally active inhibitor of prostaglandin synthetase. Clopirac is an anti-inflammatory agent.

Zaloglanstat (ISC-27864) is the inhibitor of the microsomal prostaglandin E synthase-1 (mPGES-1), and can be used to study asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases, etc.

PF-4693627 is a potent, selective and orally bioavailable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor (IC50=3 nM) for the treatment of inflammation caused by osteoarthritis (OA) and rheumatoid arthritis (RA).